Exogenous Ketones in People With Type 1 Diabetes
Primary Purpose
Ketosis, Diabetic
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Ketone ester supplement
Sponsored by
About this trial
This is an interventional prevention trial for Ketosis, Diabetic
Eligibility Criteria
Inclusion Criteria:
- Type 1 diabetes for >1 year
- Male and female aged 18-45 years old
- HbA1c <8.5% (69 mmol/mol) based on analysis from the central laboratory unit of Bern University Hospital
- Using either continuous subcutaneous insulin infusion or multiple daily injections
- Wearing a continuous glucose monitor (CGM) or flash glucose monitor (fGM)
- Written informed consent
Exclusion Criteria:
- Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the results as judged by the investigator
- Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 agonists
- Relevant diabetic complications as judged by the investigator
- Body mass index > 30 kg/m2
- Uncontrolled hypertension (>180/100 mmHg)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Low-dose KE
High-dose KE
Arm Description
141 mg/kg bodyweight of ketone esters
282 mg/kg bodyweight of ketone esters
Outcomes
Primary Outcome Measures
Change in venous blood pH
Change in blood pH over a 3 hour period from baseline following ingestion of a ketone ester drink
Secondary Outcome Measures
Blood total ketone level /beta hydroxy butyrate level
Blood glucose concentration
Substrate oxidation rates determined using indirect calorimetry, via RER (respiratory exchange ratio)
Gastro-intestinal distress symptoms via a questionnaire
Full Information
NCT ID
NCT04487678
First Posted
July 22, 2020
Last Updated
August 30, 2023
Sponsor
Insel Gruppe AG, University Hospital Bern
1. Study Identification
Unique Protocol Identification Number
NCT04487678
Brief Title
Exogenous Ketones in People With Type 1 Diabetes
Official Title
A Single-centre, Randomised, Single-blinded Crossover Study Evaluating the Metabolic Effects of a Ketone Ester Food Supplement in People With Type 1 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Prioritization of other projects
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this pilot study is to investigate the metabolic effects of exogenous ketone ester food supplements, by assessing the change in blood acid-base balance, and the level of blood beta-hydroxy-butyrate in people with type 1 diabetes during resting conditions.
Detailed Description
The ketone bodies acetoacetate, β-hydroxybutyrate (βHB) and acetone are small lipid-derived molecules that are produced in the liver under certain conditions such as starvation, very low carbohydrate intake and prolonged glycogen-depleting exercise. Ketone bodies serve as an alternative energy substrate for the brain and other metabolically active tissues under periods of low glucose availability, and can modulate carbohydrate and lipid metabolism. Previously, controlled physiological ketosis required a low carbohydrate diet, starvation or administration of acetoacetate (AcAc) salts which were all unpleasant or potentially harmful. The development of ketone esters provides an alternative method to increase βHB levels, and has been shown to be well tolerated in rodents and humans. Two examples are the R,S-1,3-butanediol acetoacetate diester and the (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester. Ingestion of either have been shown to result in short-term (0.5-6 hours) nutritional ketosis (βHB >1mM). Nutritional ketosis can therefore be achieved without the need for the impracticality of ketogenic dieting or fasting.
In recent years there has been considerable interest in ketone body food supplements due to their potential for improved exercise performance and therapeutic glucose lowering effects in people with type 2 diabetes. Exogenous ketone supplements may be of particular interest for individuals living with type 1 diabetes by serving as an alternative fuel substrate to reduce the reliance on glucose utilisation and spare endogenous glycogen and reduce the risk of hypoglycaemia in certain situations, such as exercise. Stubbs et al. (2017) found that drinks containing exogenous ketones were a practical and efficacious way to raise blood βHB levels with only a modest change in acid-base balance in healthy individuals without diabetes (after 60 min, blood pH declined from 7.41 to 7.31 following a ketone ester drink). To date, no studies have investigated the metabolic effects of ketone in people with type 1 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ketosis, Diabetic
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Single-centre, randomised, single blinded, crossover study in 6 individuals with type 1 diabetes (see inclusion/exclusion criteria)
Masking
Participant
Masking Description
There will be two intervention arms that will take place in a randomised, single blinded fashion so that participants are not aware of which dose of ketone esters they receive
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low-dose KE
Arm Type
Experimental
Arm Description
141 mg/kg bodyweight of ketone esters
Arm Title
High-dose KE
Arm Type
Experimental
Arm Description
282 mg/kg bodyweight of ketone esters
Intervention Type
Dietary Supplement
Intervention Name(s)
Ketone ester supplement
Other Intervention Name(s)
H.V.M.N Ketone Ester food supplement
Intervention Description
Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
Primary Outcome Measure Information:
Title
Change in venous blood pH
Description
Change in blood pH over a 3 hour period from baseline following ingestion of a ketone ester drink
Time Frame
Over a 3 hour period from baseline following ingestion of a ketone ester drink in people with type 1 diabetes.
Secondary Outcome Measure Information:
Title
Blood total ketone level /beta hydroxy butyrate level
Time Frame
3 hours
Title
Blood glucose concentration
Time Frame
3 hours
Title
Substrate oxidation rates determined using indirect calorimetry, via RER (respiratory exchange ratio)
Time Frame
3 hours
Title
Gastro-intestinal distress symptoms via a questionnaire
Time Frame
3 hours
10. Eligibility
Sex
Male
Gender Based
Yes
Gender Eligibility Description
Males
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Type 1 diabetes for >1 year
Male and female aged 18-45 years old
HbA1c <8.5% (69 mmol/mol) based on analysis from the central laboratory unit of Bern University Hospital
Using either continuous subcutaneous insulin infusion or multiple daily injections
Wearing a continuous glucose monitor (CGM) or flash glucose monitor (fGM)
Written informed consent
Exclusion Criteria:
Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the results as judged by the investigator
Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 agonists
Relevant diabetic complications as judged by the investigator
Body mass index > 30 kg/m2
Uncontrolled hypertension (>180/100 mmHg)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christoph Stettler, MD
Organizational Affiliation
University of Bern
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
2656155
Citation
Balasse EO, Fery F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev. 1989 May;5(3):247-70. doi: 10.1002/dmr.5610050304.
Results Reference
background
PubMed Identifier
22561291
Citation
Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, Ho M, Roberts A, Robertson J, Vanitallie TB, Veech RL. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012 Aug;63(3):401-8. doi: 10.1016/j.yrtph.2012.04.008. Epub 2012 May 3.
Results Reference
background
PubMed Identifier
25379174
Citation
Cox PJ, Clarke K. Acute nutritional ketosis: implications for exercise performance and metabolism. Extrem Physiol Med. 2014 Oct 29;3:17. doi: 10.1186/2046-7648-3-17. eCollection 2014.
Results Reference
background
PubMed Identifier
27475046
Citation
Cox PJ, Kirk T, Ashmore T, Willerton K, Evans R, Smith A, Murray AJ, Stubbs B, West J, McLure SW, King MT, Dodd MS, Holloway C, Neubauer S, Drawer S, Veech RL, Griffin JL, Clarke K. Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes. Cell Metab. 2016 Aug 9;24(2):256-68. doi: 10.1016/j.cmet.2016.07.010. Epub 2016 Jul 27.
Results Reference
background
PubMed Identifier
29473164
Citation
Egan B. The glucose-lowering effects of exogenous ketones: is there therapeutic potential? J Physiol. 2018 Apr 15;596(8):1317-1318. doi: 10.1113/JP275938. Epub 2018 Mar 24. No abstract available.
Results Reference
background
PubMed Identifier
27626197
Citation
Egan B, D'Agostino DP. Fueling Performance: Ketones Enter the Mix. Cell Metab. 2016 Sep 13;24(3):373-375. doi: 10.1016/j.cmet.2016.08.021.
Results Reference
background
PubMed Identifier
27861911
Citation
Evans M, Cogan KE, Egan B. Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation. J Physiol. 2017 May 1;595(9):2857-2871. doi: 10.1113/JP273185. Epub 2016 Dec 7.
Results Reference
background
PubMed Identifier
10702749
Citation
Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48. doi: 10.1038/sj.ijo.0801083.
Results Reference
background
PubMed Identifier
26855664
Citation
Kesl SL, Poff AM, Ward NP, Fiorelli TN, Ari C, Van Putten AJ, Sherwood JW, Arnold P, D'Agostino DP. Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Sprague-Dawley rats. Nutr Metab (Lond). 2016 Feb 4;13:9. doi: 10.1186/s12986-016-0069-y. eCollection 2016.
Results Reference
background
PubMed Identifier
29446830
Citation
Myette-Cote E, Neudorf H, Rafiei H, Clarke K, Little JP. Prior ingestion of exogenous ketone monoester attenuates the glycaemic response to an oral glucose tolerance test in healthy young individuals. J Physiol. 2018 Apr 15;596(8):1385-1395. doi: 10.1113/JP275709. Epub 2018 Mar 2. Erratum In: J Physiol. 2019 Nov;597(22):5515. Abstract corrected.
Results Reference
background
PubMed Identifier
27430501
Citation
Pinckaers PJ, Churchward-Venne TA, Bailey D, van Loon LJ. Ketone Bodies and Exercise Performance: The Next Magic Bullet or Merely Hype? Sports Med. 2017 Mar;47(3):383-391. doi: 10.1007/s40279-016-0577-y.
Results Reference
background
PubMed Identifier
6986618
Citation
Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev. 1980 Jan;60(1):143-87. doi: 10.1152/physrev.1980.60.1.143. No abstract available.
Results Reference
background
PubMed Identifier
29163194
Citation
Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, Magor-Elliott S, Hiyama S, Stirling M, Clarke K. On the Metabolism of Exogenous Ketones in Humans. Front Physiol. 2017 Oct 30;8:848. doi: 10.3389/fphys.2017.00848. eCollection 2017.
Results Reference
background
Learn more about this trial
Exogenous Ketones in People With Type 1 Diabetes
We'll reach out to this number within 24 hrs